Globomycin is used as a signal peptidase II (LspA) inhibitor to block the processing of bacterial lipoproteins in both Gram-negative (gracilicutes) and Gram-positive (firmicutes) bacteria; it exhibits antimicrobial activity against Spiroplasma melliferum with MIC values of 6.25 µM (4.1 µg/mL) for strain BC3 and 12.5 µM (8.2 µg/mL) for strain B88; it is also employed as a research tool to study lipoprotein biogenesis and secretion mechanisms, such as in investigations involving organophosphate hydrolase (OPH) processing in B. diminuta DS010 cells.